Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the reporting period ending March 19, 2026. The registrant is headquartered in Marseille, France, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a vehicle to distribute a press release (Exhibit 99.1) rather than a comprehensive financial statement.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. No comparative financial data is included in the provided document text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document references a press release dated March 19, 2026, which likely contains these details, but the content of that release is not included in the input text.
Key Facts for Investor Verification
- Verify the content of the referenced Press Release (Exhibit 99.1) for specific operational or clinical updates.
- Confirm the company's current cash position and burn rate, as no financial figures are present in this filing.
- Review the full Form 20-F for the most recent audited financial statements.